Prostaglandins in pathogenesis and treatment of multiple sclerosis

References

• Nicot, A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front. Biosci. 2009, 14, 4477–4515.
   PubMed Web of Science ®Google Scholar
• Brück, W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 2005, 252, v3–v9.
   Web of Science ®Google Scholar
• Xiang, Z., Lin, T., Reeves, S.A. 15d-PGJ2 induces apoptosis of mouse oligodendrocyte precursor cells. J. Neuroinflammation. 2007, 4, 18.
   PubMedGoogle Scholar
• Frohman, E.M., Racke, M.K., Raine, C.S. Multiple sclerosis—the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354, 942–955.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A. Venom therapy in multiple sclerosis. Neuropharmacology. 2007, 53, 353–361.
   PubMedGoogle Scholar
• Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mörk, S., Bö, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278–285.
   PubMed Web of Science ®Google Scholar
• Endres, M. Statins: potential new indications in inflammatory conditions. Atheroscler. Suppl. 2006, 7, 31–35.
   PubMed Web of Science ®Google Scholar
• Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., Weinshenker, B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343, 938–952.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki, Y., Melamed, E., Offen, D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251, 261–268.
   PubMed Web of Science ®Google Scholar
• Linington, C., Berger, T., Perry, L., Weerth, S., Hinze-Selch, D., Zhang, Y., Lu, H.C., Lassmann, H., Wekerle, H. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur. J. Immunol. 1993, 23, 1364–1372.
   PubMed Web of Science ®Google Scholar
• Oksenberg, J.R., Baranzini, S.E., Sawcer, S., Hauser, S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 2008, 9, 516–526.
   PubMed Web of Science ®Google Scholar
• Evangelou, N., Jackson, M., Beeson, D., Palace, J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 1999, 67, 203–205.
   PubMed Web of Science ®Google Scholar
• Haines, J.L., Ter-Minassian, M., Bazyk, A., Gusella, J.F., Kim, D.J., Terwedow, H., Pericak-Vance, M.A., Rimmler, J.B., Haynes, C.S., Roses, A.D., Lee, A., Shaner, B., Menold, M., Seboun, E., Fitoussi, R.P., Gartioux, C., Reyes, C., Ribierre, F., Gyapay, G., Weissenbach, J., Hauser, S.L., Goodkin, D.E., Lincoln, R., Usuku, K., Oksenberg, J.R. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 1996, 13, 469–471.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A., Mohsenzadegan, M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 2009, 31, 13–29.
   PubMed Web of Science ®Google Scholar
• Myhr, K.M., Raknes, G., Nyland, H., Vedeler, C. Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology 1999, 52, 1771–1776.
   PubMed Web of Science ®Google Scholar
• Sadovnick, A.D., Dyment, D., Ebers, G.C. Genetic epidemiology of multiple sclerosis. Epidemiol. Rev. 1997, 19, 99–106.
   PubMed Web of Science ®Google Scholar
• Kristjansdottir, G., Sandling, J.K., Bonetti, A., Roos, I.M., Milani, L., Wang, C., Gustafsdottir, S.M., Sigurdsson, S., Lundmark, A., Tienari, P.J., Koivisto, K., Elovaara, I., Pirttilä, T., Reunanen, M., Peltonen, L., Saarela, J., Hillert, J., Olsson, T., Landegren, U., Alcina, A., Fernández, O., Leyva, L., Guerrero, M., Lucas, M., Izquierdo, G., Matesanz, F., Syvänen, A.C. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J. Med. Genet. 2008, 45, 362–369.
   PubMed Web of Science ®Google Scholar
• Sarial, S., Shokrgozar, M.A., Amirzargar, A., Shokri, F., Radfar, J., Zohrevand, P., Arjang, Z., Sahraian, M.A., Lotfi, J. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran. J. Allergy. Asthma. Immunol. 2008, 7, 37–40.
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers, I.A., Aulchenko, Y.S., Ebers, G.C., Ramagopalan, S.V., Oostra, B.A., van Duijn, C.M., Hintzen, R.Q. >EVI5 is a risk gene for multiple sclerosis. Genes Immun. 2008, 9, 334–337.
   PubMed Web of Science ®Google Scholar
• Lorentzen, A.R., Smestad, C., Lie, B.A., Oturai, A.B., Akesson, E., Saarela, J., Myhr, K.M., Vartdal, F., Celius, E.G., Sørensen, P.S., Hillert, J., Spurkland, A., Harbo, H.F. The SH2D2A gene and susceptibility to multiple sclerosis. J. Neuroimmunol. 2008, 197, 152–158.
   PubMed Web of Science ®Google Scholar
• Camiña-Tato, M., Morcillo-Suárez, C., Navarro, A., Fernández, M., Horga, A., Montalban, X., Comabella, M. Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. J. Neuroimmunol. 2009, 213, 142–147.
   PubMed Web of Science ®Google Scholar
• Shokrgozar, M.A., Sarial, S., Amirzargar, A., Shokri, F., Rezaei, N., Arjang, Z., Radfar, J., Yousefi-Behzadi, M., Ali Sahraian, M., Lotfi, J. IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis. J. Clin. Immunol. 2009, 29, 747–751.
   PubMed Web of Science ®Google Scholar
• Karabon, L., Kosmaczewska, A., Bilinska, M., Pawlak, E., Ciszak, L., Jedynak, A., Jonkisz, A., Noga, L., Pokryszko-Dragan, A., Koszewicz, M., Frydecka, I. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology. 2009, 128, e787–e796.
   PubMed Web of Science ®Google Scholar
• Mero, I.L., Lorentzen, A.R., Ban, M., Smestad, C., Celius, E.G., Aarseth, J.H., Myhr, K.M., Link, J., Hillert, J., Olsson, T., Kockum, I., Masterman, T., Oturai, A.B., Søndergaard, H.B., Sellebjerg, F., Saarela, J., Kemppinen, A., Elovaara, I., Spurkland, A., Dudbridge, F., Lie, B.A., Harbo, H.F. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur. J. Hum. Genet. 2009.
   PubMedGoogle Scholar
• Ronaghi, M., Vallian, S., Etemadifar, M. CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population. Psychiatry Res. 2009, 170, 271–272.
   PubMed Web of Science ®Google Scholar
• Alcina, A., Ramagopalan, S.V., Fernández, O., Catalá-Rabasa, A., Fedetz, M., Ndagire, D., Leyva, L., Arnal, C., Delgado, C., Lucas, M., Izquierdo, G., Ebers, G.C., Matesanz, F. Hexose-6-phosphate dehydrogenase: a new risk gene for multiple sclerosis. Eur. J. Hum. Genet. 2009.
   PubMed Web of Science ®Google Scholar
• Wu, X.M., Wang, C., Zhang, K.N., Lin, A.Y., Kira, J., Hu, G.Z., Qu, X.H., Xiong, Y.Q., Cao, W.F., Gong, L.Y. Association of susceptibility to multiple sclerosis in Southern Han Chinese with HLA-DRB1, -DPB1 alleles and DRB1-DPB1 haplotypes: distinct from other populations. Mult. Scler. 2009, 15, 1422–1430.
   PubMedGoogle Scholar
• Wu, J.S., James, I., Qiu, W., Castley, A., Christiansen, F.T., Carroll, W.M., Mastaglia, F.L., Kermode, A.G. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J. Neuroimmunol. 2009, 219, 109–113.
   PubMedGoogle Scholar
• Ramil, E., Sánchez, A., González-Pérez, P., Rodríguez-Antigüedad, A., Gómez-Lozano, N., Ortiz, P., Arroyo, R., De Las Heras, V., Vilches, C., García-Merino, A. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult. Scler. 2010, 16, 139–146.
   PubMed Web of Science ®Google Scholar
• Ghabaee, M., Bayati, A., Amri Saroukolaei, S., Sahraian, M.A., Sanaati, M.H., Karimi, P., Houshmand, M., Sadeghian, H., Hashemi Chelavi, L. Analysis of HLA DR2&DQ6 (DRB1*1501, DQA1*0102, DQB1*0602) haplotypes in Iranian patients with multiple sclerosis. Cell. Mol. Neurobiol. 2009, 29, 109–114.
   PubMed Web of Science ®Google Scholar
• Barcellos, L.F., Oksenberg, J.R., Green, A.J., Bucher, P., Rimmler, J.B., Schmidt, S., Garcia, M.E., Lincoln, R.R., Pericak-Vance, M.A., Haines, J.L., Hauser, S.L. Multiple Sclerosis Genetics Group. Genetic basis for clinical expression in multiple sclerosis. Brain 2002, 125, 150–158.
   PubMed Web of Science ®Google Scholar
• Schmidt, H., Williamson, D., Ashley-Koch, A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 2007, 165, 1097–1109.
   PubMed Web of Science ®Google Scholar
• Sospedra, M., Muraro, P.A., Stefanová, I., Zhao, Y., Chung, K., Li, Y., Giulianotti, M., Simon, R., Mariuzza, R., Pinilla, C., Martin, R. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J. Immunol. 2006, 176, 1951–1961.
   PubMed Web of Science ®Google Scholar
• DeLuca, G.C., Ramagopalan, S.V., Herrera, B.M., Dyment, D.A., Lincoln, M.R., Montpetit, A., Pugliatti, M., Barnardo, M.C., Risch, N.J., Sadovnick, A.D., Chao, M., Sotgiu, S., Hudson, T.J., Ebers, G.C. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc. Natl. Acad. Sci. USA. 2007, 104, 20896–20901.
   PubMed Web of Science ®Google Scholar
• Silva, A.M., Bettencourt, A., Pereira, C., Santos, E., Carvalho, C., Mendonça, D., Costa, P.P., Monteiro, L., Martins, B. Protective role of the HLA-A*02 allele in Portuguese patients with multiple sclerosis. Mult. Scler. 2009, 15, 771–774.
   PubMed Web of Science ®Google Scholar
• Pastorino, R., Menni, C., Barca, M., Foco, L., Saddi, V., Gazzaniga, G., Ferrai, R., Mascaretti, L., Dudbridge, F., Berzuini, C., Murgia, S.B., Piras, M.L., Ticca, A., Bitti, P.P., Bernardinelli, L. Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia. PLoS ONE. 2009, 4, e6526.
   PubMed Web of Science ®Google Scholar
• Klotz, L., Schmidt, S., Heun, R., Klockgether, T., Kölsch, H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci. Lett. 2009, 449, 81–83.
   PubMedGoogle Scholar
• Mirshafiey, A. Novel promising therapeutic agents in multiple sclerosis. Recent Pat. Inflamm. Allergy Drug Discov. 2007, 1, 218–214.
   PubMedGoogle Scholar
• Bjartmar, C., Wujek, J.R., Trapp, B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206, 165–171.
   PubMed Web of Science ®Google Scholar
• Neumann, H., Medana, I.M., Bauer, J., Lassmann, H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002, 25, 313–319.
   PubMed Web of Science ®Google Scholar
• Redford, E.J., Smith, K.J., Gregson, N.A., Davies, M., Hughes, P., Gearing, A.J., Miller, K., Hughes, R.A. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 1997, 120, 1895–1905.
   PubMed Web of Science ®Google Scholar
• Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., Ravid, R., Rajewsky, K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192, 393–404.
   PubMed Web of Science ®Google Scholar
• Jacobsen, M., Cepok, S., Quak, E., Happel, M., Gaber, R., Ziegler, A., Schock, S., Oertel, W.H., Sommer, N., Hemmer, B. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002, 125, 538–550.
   PubMed Web of Science ®Google Scholar
• Lafaille, J.J., Keere, F.V., Hsu, A.L., Baron, J.L., Haas, W., Raine, C.S., Tonegawa, S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 1997, 186, 307–312.
   PubMed Web of Science ®Google Scholar
• Bettelli, E., Oukka, M., Kuchroo, V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8, 345–350.
   PubMed Web of Science ®Google Scholar
• Thakker, P., Leach, M.W., Kuang, W., Benoit, S.E., Leonard, J.P., Marusic, S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178, 2589–2598.
   PubMed Web of Science ®Google Scholar
• Owens, T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr. Opin. Neurol. 2003, 16, 259–265.
   PubMedGoogle Scholar
• Peterson, L.K., Fujinami, R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007, 184, 37–44.
   PubMed Web of Science ®Google Scholar
• Constam, D.B., Philipp, J., Malipiero, U.V., ten Dijke, P., Schachner, M., Fontana, A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. 1992, 148, 1404–1410.
   PubMed Web of Science ®Google Scholar
• Huan, J., Culbertson, N., Spencer, L., Bartholomew, R., Burrows, G.G., Chou, Y.K., Bourdette, D., Ziegler, S.F., Offner, H., Vandenbark, A.A. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 2005, 81, 45–52.
   PubMed Web of Science ®Google Scholar
• Barnstein, B.O., Li, G., Wang, Z., Kennedy, S., Chalfant, C., Nakajima, H., Bunting, K.D., Ryan, J.J. Stat5 expression is required for IgE-mediated mast cell function. J. Immunol. 2006, 177, 3421–3426.
   PubMedGoogle Scholar
• Alcaro, M.C., Papini, A.M. Contribution of peptides to multiple sclerosis research. Biopolymers. 2006, 84, 349–367.
   PubMed Web of Science ®Google Scholar
• Bar-Or, A. Human immune studies in multiple sclerosis. Adv. Neurol. 2006, 98, 91–109.
   PubMedGoogle Scholar
• Birnbaum, G. Making the diagnosis of multiple sclerosis. Adv. Neurol. 2006, 98, 111–124.
   PubMedGoogle Scholar
• Goldman, M.D., Cohen, J.A., Fox, R.J., Bethoux, F.A. Multiple sclerosis: treating symptoms, and other general medical issues. Cleve. Clin. J. Med. 2006, 73, 177–186.
   PubMed Web of Science ®Google Scholar
• Derwenskus, J., Lublin, F.D. Use of interferon-beta in the treatment of multiple sclerosis. Adv. Neurol. 2006, 98, 257–271.
   PubMedGoogle Scholar
• Goodin, D.S. Treatment of multiple sclerosis with human beta interferon. Int. MS J. 2005, 12, 96–108.
   PubMedGoogle Scholar
• Milligan, N.M., Newcombe, R., Compston, D.A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatr. 1987, 50, 511–516.
   PubMed Web of Science ®Google Scholar
• Mirshafiey, A., Saadat, F., Attar, M., Di Paola, R., Sedaghat, R., Cuzzocrea, S. Design of a new line in treatment of experimental rheumatoid arthritis by artesunate. Immunopharmacol. Immunotoxicol. 2006, 28, 397–410.
   PubMed Web of Science ®Google Scholar
• Stangel, M., Gold, R., Gass, A., Haas, J., Jung, S., Elias, W., Zettl, U.K. Current issues in immunomodulatory treatment of multiple sclerosis—a practical approach. J. Neurol. 2006, 253, I32–I36.
   Google Scholar
• Mirshafiey, A., Matsuo, H., Nakane, S., Rehm, B.H., Koh, C.S., Miyoshi, S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol. Immunotoxicol. 2005, 27, 255–265.
   PubMed Web of Science ®Google Scholar
• Bailie, M.B., Standiford, T.J., Laichalk, L.L., Coffey, M.J., Strieter, R., Peters-Golden, M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. 1996, 157, 5221–5224.
   PubMed Web of Science ®Google Scholar
• Benjamim, C.F., Canetti, C., Cunha, F.Q., Kunkel, S.L., Peters-Golden, M. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J. Immunol. 2005, 174, 1616–1620.
   PubMedGoogle Scholar
• DeWitt, D.L. Cox-2-selective inhibitors: the new super aspirins. Mol. Pharmacol. 1999, 55, 625–631.
   PubMed Web of Science ®Google Scholar
• Ferreira, S.H., Moncada, S., Vane, J.R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol. 1971, 231, 237–239.
   PubMedGoogle Scholar
• Gijón, M.A., Spencer, D.M., Kaiser, A.L., Leslie, C.C. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J. Cell Biol. 1999, 145, 1219–1232.
   PubMed Web of Science ®Google Scholar
• Nalefski, E.A., Sultzman, L.A., Martin, D.M., Kriz, R.W., Towler, P.S., Knopf, J.L., Clark, J.D. Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain. J. Biol. Chem. 1994, 269, 18239–18249.
   PubMed Web of Science ®Google Scholar
• Parente, L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. 2001, 28, 2375–2382.
   PubMed Web of Science ®Google Scholar
• Samuelsson, B., Dahlén, S.E., Lindgren, J.A., Rouzer, C.A., Serhan, C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987, 237, 1171–1176.
   PubMed Web of Science ®Google Scholar
• Smith, W.L., Garavito, R.M., DeWitt, D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 271, 33157–33160.
   PubMed Web of Science ®Google Scholar
• Hata, A.N., Breyer, R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103, 147–166.
   PubMed Web of Science ®Google Scholar
• Saito, S., Tsuda, H., Michimata, T. Prostaglandin D2 and reproduction. Am. J. Reprod. Immunol. 2002, 47, 295–302.
   PubMedGoogle Scholar
• Phillis, J.W., Horrocks, L.A., Farooqui, A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 2006, 52, 201–243.
   PubMed Web of Science ®Google Scholar
• Chandrasekharan, N.V., Dai, H., Roos, K.L., Evanson, N.K., Tomsik, J., Elton, T.S., Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA. 2002, 99, 13926–13931.
   PubMed Web of Science ®Google Scholar
• Davies, N.M., Good, R.L., Roupe, K.A., Yáñez, J.A. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3. J. Pharm. Pharm. Sci. 2004, 7, 217–226.
   PubMed Web of Science ®Google Scholar
• Khanapure, S.P., Garvey, D.S., Janero, D.R., Letts, L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem. 2007, 7, 311–340.
   PubMed Web of Science ®Google Scholar
• Schaiff, W.T., Carlson, M.G., Smith, S.D., Levy, R., Nelson, D.M., Sadovsky, Y. Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J. Clin. Endocrinol. Metab. 2000, 85, 3874–3881.
   PubMed Web of Science ®Google Scholar
• Forman, B.M., Tontonoz, P., Chen, J., Brun, R.P., Spiegelman, B.M., Evans, R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995, 83, 803–812.
   PubMed Web of Science ®Google Scholar
• Gervais, F.G., Cruz, R.P., Chateauneuf, A., Gale, S., Sawyer, N., Nantel, F., Metters, K.M., O’neill, G.P. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J. Allergy Clin. Immunol. 2001, 108, 982–988.
   PubMed Web of Science ®Google Scholar
• Gosset, P., Bureau, F., Angeli, V., Pichavant, M., Faveeuw, C., Tonnel, A.B., Trottein, F. Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J. Immunol. 2003, 170, 4943–4952.
   PubMed Web of Science ®Google Scholar
• Kabashima, K., Narumiya, S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot. Essent. Fatty Acids. 2003, 69, 187–194.
   PubMed Web of Science ®Google Scholar
• Tanaka, K., Hirai, H., Takano, S., Nakamura, M., Nagata, K. Effects of prostaglandin D2 on helper T cell functions. Biochem. Biophys. Res. Commun. 2004, 316, 1009–1014.
   PubMedGoogle Scholar
• Monneret, G., Gravel, S., Diamond, M., Rokach, J., Powell, W.S. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001, 98, 1942–1948.
   PubMed Web of Science ®Google Scholar
• Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., Nagata, K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 2001, 193, 255–261.
   PubMed Web of Science ®Google Scholar
• Kostenis, E., Ulven, T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. 2006, 12, 148–158.
   PubMedGoogle Scholar
• Nagata, K., Hirai, H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot. Essent. Fatty Acids. 2003, 69, 169–177.
   PubMed Web of Science ®Google Scholar
• Xue, L., Gyles, S.L., Wettey, F.R., Gazi, L., Townsend, E., Hunter, M.G., Pettipher, R. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J. Immunol. 2005, 175, 6531–6536.
   PubMed Web of Science ®Google Scholar
• Gudis, K., Sakamoto, C. The role of cyclooxygenase in gastric mucosal protection. Dig. Dis. Sci. 2005, 50, S16–S23.
   PubMed Web of Science ®Google Scholar
• Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., Kudo, I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 2000, 275, 32775–32782.
   PubMed Web of Science ®Google Scholar
• Tanikawa, N., Ohmiya, Y., Ohkubo, H., Hashimoto, K., Kangawa, K., Kojima, M., Ito, S., Watanabe, K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 2002, 291, 884–889.
   PubMed Web of Science ®Google Scholar
• Abramovitz, M., Wong, E., Cox, M.E., Richardson, C.D., Li, C., Vickers, P.J. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem. 1993, 215, 105–111.
   PubMedGoogle Scholar
• Sugimoto, Y., Narumiya, S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282, 11613–11617.
   PubMed Web of Science ®Google Scholar
• Trebino, C.E., Stock, J.L., Gibbons, C.P., Naiman, B.M., Wachtmann, T.S., Umland, J.P., Pandher, K., Lapointe, J.M., Saha, S., Roach, M.L., Carter, D., Thomas, N.A., Durtschi, B.A., McNeish, J.D., Hambor, J.E., Jakobsson, P.J., Carty, T.J., Perez, J.R., Audoly, L.P. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA. 2003, 100, 9044–9049.
   PubMed Web of Science ®Google Scholar
• Khasar, S.G., Gold, M.S., Levine, J.D. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci. Lett. 1998, 256, 17–20.
   PubMed Web of Science ®Google Scholar
• Stock, J.L., Shinjo, K., Burkhardt, J., Roach, M., Taniguchi, K., Ishikawa, T., Kim, H.S., Flannery, P.J., Coffman, T.M., McNeish, J.D., Audoly, L.P. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J. Clin. Invest. 2001, 107, 325–331.
   PubMedGoogle Scholar
• Minami, T., Nakano, H., Kobayashi, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., Narumiya, S., Ito, S. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br. J. Pharmacol. 2001, 133, 438–444.
   PubMed Web of Science ®Google Scholar
• Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto, Y., Kobayashi, T., Ushikubi, F., Aze, Y., Eguchi, N., Urade, Y., Yoshida, N., Kimura, K., Mizoguchi, A., Honda, Y., Nagai, H., Narumiya, S. Prostaglandin D2 as a mediator of allergic asthma. Science 2000, 287, 2013–2017.
   PubMed Web of Science ®Google Scholar
• Kabashima, K., Sakata, D., Nagamachi, M., Miyachi, Y., Inaba, K., Narumiya, S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 2003, 9, 744–749.
   PubMedGoogle Scholar
• Nataraj, C., Thomas, D.W., Tilley, S.L., Nguyen, M.T., Mannon, R., Koller, B.H., Coffman, T.M. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J. Clin. Invest. 2001, 108, 1229–1235.
   PubMed Web of Science ®Google Scholar
• McCoy, J.M., Wicks, J.R., Audoly, L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 2002, 110, 651–658.
   PubMed Web of Science ®Google Scholar
• Bjarnason, I., Hayllar, J., MacPherson, A.J., Russell, A.S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104, 1832–1847.
   PubMed Web of Science ®Google Scholar
• Kunikata, T., Yamane, H., Segi, E., Matsuoka, T., Sugimoto, Y., Tanaka, S., Tanaka, H., Nagai, H., Ichikawa, A., Narumiya, S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat. Immunol. 2005, 6, 524–531.
   PubMed Web of Science ®Google Scholar
• Yang, L., Yamagata, N., Yadav, R., Brandon, S., Courtney, R.L., Morrow, J.D., Shyr, Y., Boothby, M., Joyce, S., Carbone, D.P., Breyer, R.M. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 2003, 111, 727–735.
   PubMed Web of Science ®Google Scholar
• de Leval, X., Hanson, J., David, J.L., Masereel, B., Pirotte, B., Dogné, J.M. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr. Med. Chem. 2004, 11, 1243–1252.
   PubMed Web of Science ®Google Scholar
• Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., Narumiya, S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388, 678–682.
   PubMed Web of Science ®Google Scholar
• Jaffar, Z., Wan, K.S., Roberts, K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 2002, 169, 5997–6004.
   PubMed Web of Science ®Google Scholar
• Takahashi, Y., Tokuoka, S., Masuda, T., Hirano, Y., Nagao, M., Tanaka, H., Inagaki, N., Narumiya, S., Nagai, H. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol. 2002, 137, 315–322.
   PubMed Web of Science ®Google Scholar
• Watanabe, K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat. 2002, 68–69, 401–407.
   PubMedGoogle Scholar
• Pierce, K.L., Bailey, T.J., Hoyer, P.B., Gil, D.W., Woodward, D.F., Regan, J.W. Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J. Biol. Chem. 1997, 272, 883–887.
   PubMed Web of Science ®Google Scholar
• Sugimoto, Y., Yamasaki, A., Segi, E., Tsuboi, K., Aze, Y., Nishimura, T., Oida, H., Yoshida, N., Tanaka, T., Katsuyama, M., Hasumoto, K., Murata, T., Hirata, M., Ushikubi, F., Negishi, M., Ichikawa, A., Narumiya, S. Failure of parturition in mice lacking the prostaglandin F receptor. Science. 1997, 277, 681–683.
   PubMed Web of Science ®Google Scholar
• Tilley, S.L., Coffman, T.M., Koller, B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 2001, 108, 15–23.
   PubMed Web of Science ®Google Scholar
• Wang, M.T., Honn, K.V., Nie, D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007, 26, 525–534.
   PubMed Web of Science ®Google Scholar
• Kalyvas, A., David, S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron. 2004, 41, 323–335.
   PubMed Web of Science ®Google Scholar
• Marusic, S., Thakker, P., Pelker, J.W., Stedman, N.L., Lee, K.L., McKew, J.C., Han, L., Xu, X., Wolf, S.F., Borey, A.J., Cui, J., Shen, M.W., Donahue, F., Hassan-Zahraee, M., Leach, M.W., Shimizu, T., Clark, J.D. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 2008, 204, 29–37.
   PubMed Web of Science ®Google Scholar
• Marusic, S., Leach, M.W., Pelker, J.W., Azoitei, M.L., Uozumi, N., Cui, J., Shen, M.W., DeClercq, C.M., Miyashiro, J.S., Carito, B.A., Thakker, P., Simmons, D.L., Leonard, J.P., Shimizu, T., Clark, J.D. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 2005, 202, 841–851.
   PubMed Web of Science ®Google Scholar
• Dore-Duffy, P., Donaldson, J.O., Koff, T., Longo, M., Perry, W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology. 1986, 36, 1587–1590.
   PubMedGoogle Scholar
• Dore-Duffy, P., Ho, S.Y., Donovan, C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology. 1991, 41, 322–324.
   PubMedGoogle Scholar
• Rosnowska, M., Noworyta, T., Cendrowski, W. [Cerebrospinal fluid prostaglandins in multiple sclerosis. Preliminary report]. Neurol. Neurochir. Pol. 1980, 14, 23–26.
   PubMedGoogle Scholar
• Mattsson, N., Yaong, M., Rosengren, L., Blennow, K., Månsson, J.E., Andersen, O., Zetterberg, H., Haghighi, S., Zho, I., Pratico, D. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J. Intern. Med. 2009, 265, 459–464.
   PubMed Web of Science ®Google Scholar
• Misko, T.P., Trotter, J.L., Cross, A.H. Mediation of inflammation by encephalitogenic cells: interferon gamma induction of nitric oxide synthase and cyclooxygenase 2. J. Neuroimmunol. 1995, 61, 195–204.
   PubMed Web of Science ®Google Scholar
• Shivastava, K.C., Fog, T., Clausen, J. The synthesis of prostaglandins in platelets from patients with multiple sclerosis. Acta Neurol. Scand. 1975, 51, 193–199.
   PubMedGoogle Scholar
• Egg, D., Herold, M., Rumpl, E., Günther, R. Prostaglandin F2 alpha levels in human cerebrospinal fluid in normal and pathological conditions. J. Neurol. 1980, 222, 239–248.
   PubMedGoogle Scholar
• Greco, A., Minghetti, L., Sette, G., Fieschi, C., Levi, G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology. 1999, 53, 1876–1879.
   PubMed Web of Science ®Google Scholar
• Kagitani-Shimono, K., Mohri, I., Oda, H., Ozono, K., Suzuki, K., Urade, Y., Taniike, M. Lipocalin-type prostaglandin D synthase (beta-trace) is upregulated in the alphaB-crystallin-positive oligodendrocytes and astrocytes in the chronic multiple sclerosis. Neuropathol. Appl. Neurobiol. 2006, 32, 64–73.
   PubMedGoogle Scholar
• Melegos, D.N., Freedman, M.S., Diamandis, E.P. Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. Prostaglandins. 1997, 54, 463–474.
   PubMedGoogle Scholar
• Saso, L., Leone, M.G., Sorrentino, C., Giacomelli, S., Silvestrini, B., Grima, J., Li, J.C., Samy, E., Mruk, D., Cheng, C.Y. Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor. Biochem. Mol. Biol. Int. 1998, 46, 643–656.
   PubMedGoogle Scholar
• Taniguchi, H., Mohri, I., Okabe-Arahori, H., Kanekiyo, T., Kagitani-Shimono, K., Wada, K., Urade, Y., Nakayama, M., Ozono, K., Taniike, M. Early induction of neuronal lipocalin-type prostaglandin D synthase after hypoxic-ischemic injury in developing brains. Neurosci. Lett. 2007, 420, 39–44.
   PubMedGoogle Scholar
• Mattsson, N., Haghighi, S., Andersen, O., Yao, Y., Rosengren, L., Blennow, K., Praticò, D., Zetterberg, H. Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neurosci. Lett. 2007, 414,233–236.
   PubMed Web of Science ®Google Scholar
• Greco, A., Minghetti, L., Levi, G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2000, 25, 1357–1364.
   PubMed Web of Science ®Google Scholar
• Greco, A., Minghetti, L., Puopolo, M., Cannoni, S., Romano, S., Pozzilli, C., Levi, G. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2004, 224, 23–27.
   PubMed Web of Science ®Google Scholar
• Comabella, M., Pradillo, J.M., Fernandez, M., Río, J., Lizasoain, I., Julià, E., Moro, M.A., Sastre-Garriga, J., Montalban, X. Plasma levels of 15d-PGJ2 are not altered in multiple sclerosis. Eur J Neurol. 2009, 16, 1197–1201.
   PubMedGoogle Scholar
• Skarke, C., Schuss, P., Kirchhof, A., Doehring, A., Geisslinger, G., Lötsch, J. Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics. 2007, 8, 1643–1660.
   PubMed Web of Science ®Google Scholar
• Yang, H., Chen, C. Cyclooxygenase-2 in synaptic signaling. Curr. Pharm. Des. 2008, 14, 1443–1451.
   PubMed Web of Science ®Google Scholar
• Mestre, L., Correa, F., Docagne, F., Clemente, D., Guaza, C. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler’s virus infection. Biochem. Pharmacol. 2006, 72, 869–880.
   PubMedGoogle Scholar
• Repovic, P., Mi, K., Benveniste, E.N. Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide. Glia. 2003, 42, 433–446.
   Google Scholar
• Davies, N.M., Longstreth, J., Jamali, F. Misoprostol therapeutics revisited. Pharmacotherapy. 2001, 21, 60–73.
   PubMed Web of Science ®Google Scholar
• Reder, A.T., Arnason, B.G. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995, 45, 1097–1100.
   PubMed Web of Science ®Google Scholar
• Reder, A.T., Thapar, M., Sapugay, A.M., Jensen, M.A. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J. Neuroimmunol. 1994, 54, 117–127.
   PubMedGoogle Scholar
• Porrini, A.M., Reder, A.T. IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell. Immunol. 1994, 157, 428–438.
   PubMedGoogle Scholar
• Chao, R., Clowers, D.E. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch. Phys. Med. Rehabil. 1994, 75, 276–278.
   PubMedGoogle Scholar
• Landtblom, A.M. Treatment of erectile dysfunction in multiple sclerosis. Expert Rev. Neurother. 2006, 6, 931–935.
   PubMedGoogle Scholar
• Cunnane, S.C., Manku, M.S., Horrobin, D.F. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 1979, 5, 403–414.
   PubMed Web of Science ®Google Scholar
• Dore-Duffy, P., Zurier, R.B. Lymphocyte adherence in multiple sclerosis: effect of aspirin. J. Clin. Invest. 1979, 63, 154–157.
   PubMedGoogle Scholar
• DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J. Neurol. 2003, 250, 542–545.
   PubMed Web of Science ®Google Scholar
• Pollak, Y., Ovadia, H., Orion, E., Yirmiya, R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J. Neuroimmunol. 2003, 137, 100–108.
   PubMedGoogle Scholar
• Shapira, L., Ayalon, S., Brenner, T. Effects of Porphyromonas gingivalis on the central nervous system: activation of glial cells and exacerbation of experimental autoimmune encephalomyelitis. J. Periodontol. 2002, 73, 511–516.
   PubMedGoogle Scholar
• Yao, C., Sakata, D., Esaki, Y., Li, Y., Matsuoka, T., Kuroiwa, K., Sugimoto, Y., Narumiya, S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 2009, 15,633–640.
   PubMed Web of Science ®Google Scholar
• Sierra, A., Ferrer, I., Arbizu, T., Buendía, E. [Multiple sclerosis: IL-2, IFN-tau and PGE2 secretion in mononuclear cell cultures stimulated with PHA and the effect of these cytokines on oligodendroglial cells]. Neurologia. 1992, 7, 247–253.
   PubMedGoogle Scholar
• DuBois, J.H., Cuzner, M.L. Regulation of lymphocyte activation by PGE2 in multiple sclerosis. J. Neurol. Sci. 1984, 65, 211–219.
   PubMedGoogle Scholar
• Kihara, Y., Matsushita, T., Kita, Y., Uematsu, S., Akira, S., Kira, J., Ishii, S., Shimizu, T. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2009, 106, 21807–21812.
   PubMed Web of Science ®Google Scholar
• Prigione, I., Benvenuto, F., Bocca, P., Battistini, L., Uccelli, A., Pistoia, V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009, 27, 693–702.
   PubMed Web of Science ®Google Scholar
• Harbige, L.S., Layward, L., Morris-Downes, M.M., Dumonde, D.C., Amor, S. The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production. Clin. Exp. Immunol. 2000, 122, 445–452.
   PubMedGoogle Scholar
• Molina-Holgado, E., Arévalo-Martín, A., Ortiz, S., Vela, J.M., Guaza, C. Theiler’s virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci. Lett. 2002, 324, 237–241.
   PubMed Web of Science ®Google Scholar
• Salinthone, S., Schillace, R.V., Marracci, G.H., Bourdette, D.N., Carr, D.W. Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells. J. Neuroimmunol. 2008, 199,46–55.
   PubMed Web of Science ®Google Scholar
• Zhuang, H., Kim, Y.S., Namiranian, K., Doré, S. Prostaglandins of J series control heme oxygenase expression: potential significance in modulating neuroinflammation. Ann. N. Y. Acad. Sci. 2003, 993, 208–216; discussion 287.
   PubMed Web of Science ®Google Scholar
• Bernardo, A., Minghetti, L. Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. PPAR Res. 2008, 2008, 864140.
   Google Scholar
• Diab, A., Deng, C., Smith, J.D., Hussain, R.Z., Phanavanh, B., Lovett-Racke, A.E., Drew, P.D., Racke, M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2002, 168, 2508–2515.
   PubMed Web of Science ®Google Scholar
• Diab, A., Hussain, R.Z., Lovett-Racke, A.E., Chavis, J.A., Drew, P.D., Racke, M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148, 116–126.
   PubMed Web of Science ®Google Scholar
• Penberthy, W.T. Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis. PPAR Res. 2009.
   PubMedGoogle Scholar
• Racke, M.K., Gocke, A.R., Muir, M., Diab, A., Drew, P.D., Lovett-Racke, A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 2006, 136, 700–703.
   PubMedGoogle Scholar
• Natarajan, C., Bright, J.J. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 2002, 3, 59–70.
   PubMedGoogle Scholar
• Raikwar, H.P., Muthian, G., Rajasingh, J., Johnson, C.N., Bright, J.J. PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2. J. Neuroimmunol. 2006, 178, 76–86.
   PubMedGoogle Scholar
• Bernardo, A., Minghetti, L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 2006, 12, 93–109.
   PubMed Web of Science ®Google Scholar
• Drew, P.D., Chavis, J.A. The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells. J. Neuroimmunol. 2001, 115, 28–35.
   PubMedGoogle Scholar
• Drew, P.D., Storer, P.D., Xu, J., Chavis, J.A. Hormone regulation of microglial cell activation: relevance to multiple sclerosis. Brain Res. Brain Res. Rev. 2005, 48, 322–327.
   PubMedGoogle Scholar
• Storer, P.D., Xu, J., Chavis, J.A., Drew, P.D. Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J. Neurosci. Res. 2005, 80, 66–74.
   PubMedGoogle Scholar
• Chearwae, W., Bright, J.J. 15-deoxy-Delta(12,14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J. Clin. Immunol. 2008, 28, 558–570.
   PubMed Web of Science ®Google Scholar
• Evers, S., Masur, H., Sörös, P., Brilla, R., Husstedt, I.W. Prostaglandin analog mechanisms are not effective in refractory chronic cluster headache. Headache. 1998, 38, 618–620.
   PubMedGoogle Scholar